Seminavis aegyptiaca sp. Nov., a new amphoroid diatom species from estuary epilithon of the river–nile damietta branch, Egypt

During a recent floristic–taxonomic study on the algal flora, including diatoms, from the estuary of the Damietta Branch of the Nile in Egypt, an interesting epilithic diatom species belonging to the genus Seminavis (Naviculaceae) was collected and investigated using both light and scanning electron microscopy. This new diatom species shares morphologically some taxonomic diagnostic features with other related taxa such as S. insignis, S. robusta, and S. ventricosa. However, it still differs by having ventral central striae that are shorter and more or less straight in the middle of the smaller frustules to be clearly radiate in the larger ones and then become geniculate and only radiate near the poles, the central raphe endings are externally more distantly spaced than in the similar species, the elongate central nodule is internally less prominent, and the areola density is much denser. Therefore, we here describe it as Seminavis aegyptiaca sp. nov. Hydrochemical analyses revealed that S. aegyptiaca commonly inhabits typical marine, with a weak tendency towards brackish water, habitats. It was found to be tolerant to meso–eutrophic, nutrient–enriched conditions, based on the data available on seasonal concentrations of N and P compounds. These findings not only contribute to the inventory of Egyptian diatoms, but also increase our understanding of the autecology and distribution of this relatively poorly–known diatom genus

Seminavis aegyptiaca sp. nov., a new amphoroid diatom species from estuary epilithon of the River-Nile Damietta Branch, Egypt

[EN] During a recent floristic–taxonomic study on the algal flora, including diatoms, from the estuary of the Damietta Branch of the Nile in Egypt, an interesting epilithic diatom species belonging to the genus Seminavis (Naviculaceae) was collected and investigated using both light and scanning electron microscopy. This new diatom species shares morphologically some taxonomic diagnostic features with other related taxa such as S. insignis, S. robusta, and S. ventricosa. However, it still differs by having ventral central striae that are shorter and more or less straight in the middle of the smaller frustules to be clearly radiate in the larger ones and then become geniculate and only radiate near the poles, the central raphe endings are externally more distantly spaced than in the similar species, the elongate central nodule is internally less prominent, and the areola density is much denser. Therefore, we here describe it as Seminavis aegyptiaca sp. nov. Hydrochemical analyses revealed that S. aegyptiaca commonly inhabits typical marine, with a weak tendency towards brackish water, habitats. It was found to be tolerant to meso–eutrophic, nutrient–enriched conditions, based on the data available on seasonal concentrations of N and P compounds. These findings not only contribute to the inventory of Egyptian diatoms, but also increase our understanding of the autecology and distribution of this relatively poorly–known diatom genusSIThis work was a part of the PhyBiO project funded by the Italian Ministry of Foreign Affairs and International Cooperation (MAECI) to the MUSE Post–Doc Abdullah A. Saber for the academic year 2018/201

The reporting of methods for reducing and detecting bias: an example from the WHO Misoprostol Third Stage of Labour equivalence randomised controlled trial

BACKGROUND: The aim of this article is to explore ways in which selection bias and ascertainment bias can be reduced and investigated in trials, by using the example of a drug trial carried out in both developed and developing countries in hospital delivery wards. METHODS: We describe an innovative and practical design for the boxes for packing the drugs as a way of increasing the security of allocation concealment and blinding. We also assess ascertainment bias using sensitivity analyses, as some unblinding could have occurred due to a potential side effect of one of the drugs. RESULTS: The sensitivity analyses indicated that the conclusions about the relative effects of the treatments could be maintained even in the unlikely worst-case scenarios. CONCLUSIONS: Detailed description of the procedures protecting against common biases and of the assessment of ascertainment bias in this trial should allow readers to confidently appraise and interpret the results obtained. In addition, our experiences will assist others in planning trials in the future

Passivation behaviour of Alloy 31 (UNS N08031) in polluted phosphoric acid at different temperatures

The influence of temperature (20–80 °C) and chloride concentration (0.06–0.42 wt.% KCl) on the electrochemical behaviour of the UNS N08031 was studied in 40 wt.% polluted phosphoric acid solution. Passivation behaviour was investigated by using potentiostatic tests at different potentials. From the linear regions of the log i vs. log t transients, the parameter n was obtained. The results showed that the applied potential hardly affects on the passivation rate n. However, n values decreased when temperature increased. The values of n demonstrated that the passive film formed on Alloy 31 was compact and highly protective.The authors express their gratitude to the MAEC of Spain (PCI Mediterraneo C/8196/07, C/018046/08, D/023608/09 and D/030177/10), to Programa de Apoyo a la Investigacion y Desarrollo de la UPV (PAID-06-09) and to the Generalitat Valenciana (GV/2011/093) for the financial support and to Dr. Asuncion Jaime for her translation assistance.Escrivá Cerdán, C.; Blasco Tamarit, ME.; García García, DM.; García Antón, J.; Guenbour, A. (2012). Passivation behaviour of Alloy 31 (UNS N08031) in polluted phosphoric acid at different temperatures. Corrosion Science. 56:114-122. https://doi.org/10.1016/j.corsci.2011.11.014S1141225

In vitro cytotoxicity of Withania somnifera (L.) roots and fruits on oral squamous cell carcinoma cell lines: a study supported by flow cytometry, spectral, and computational investigations

Oral cancer is a severe health problem that accounts for an alarmingly high number of fatalities worldwide. Withania somnifera (L.) Dunal has been extensively studied against various tumor cell lines from different body organs, rarely from the oral cavity. We thus investigated the cytotoxicity of W. somnifera fruits (W-F) and roots (W-R) hydromethanolic extracts and their chromatographic fractions against oral squamous cell carcinoma (OSCC) cell lines [Ca9-22 (derived from gingiva), HSC-2, HSC-3, and HSC-4 (derived from tongue)] and three normal oral mesenchymal cells [human gingival fibroblast (HGF), human periodontal ligament fibroblast (HPLF), and human pulp cells (HPC)] in comparison to standard drugs. The root polar ethyl acetate (W-R EtOAc) and butanol (W-R BuOH) fractions exhibited the strongest cytotoxicity against the Ca9-22 cell line (CC50 = 51.8 and 40.1 μg/mL, respectively), which is relatively the same effect as 5-FU at CC50 = 69.4 μM and melphalan at CC50 = 36.3 μM on the same cancer cell line. Flow cytometric analysis revealed changes in morphology as well as in the cell cycle profile of the W-R EtOAc and W-R BuOH-treated oral cancer Ca9-22 cells compared to the untreated control. The W-R EtOAc (125 μg/mL) exerted morphological changes and induced subG1 accumulation, suggesting apoptotic cell death. A UHPLC MS/MS analysis of the extract enabled the identification of 26 compounds, mainly alkaloids, withanolides, withanosides, and flavonoids. Pharmacophore-based inverse virtual screening proposed that BRD3 and CDK2 are the cancer-relevant targets for the annotated withanolides D (18) and O (12), and the flavonoid kaempferol (11). Molecular modeling studies highlighted the BRD3 and CDK2 as the most probable oncogenic targets of anticancer activity of these molecules. These findings highlight W. somnifera’s potential as an affordable source of therapeutic agents for a range of oral malignancies

Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy

Arrhythmogenic cardiomyopathy (ACM) is an inherited arrhythmia syndrome characterized by severe structural and electrical cardiac phenotypes, including myocardial fibrofatty replacement and sudden cardiac death. Clinical management of ACM is largely palliative, owing to an absence of therapies that target its underlying pathophysiology, which stems partially from our limited insight into the condition. Following identification of deceased ACM probands possessing ANK2 rare variants and evidence of ankyrin-B loss of function on cardiac tissue analysis, an ANK2 mouse model was found to develop dramatic structural abnormalities reflective of human ACM, including biventricular dilation, reduced ejection fraction, cardiac fibrosis, and premature death. Desmosomal structure and function appeared preserved in diseased human and murine specimens in the presence of markedly abnormal \u3b2-catenin expression and patterning, leading to identification of a previously unknown interaction between ankyrin-B and \u3b2-catenin. A pharmacological activator of the WNT/\u3b2-catenin pathway, SB-216763, successfully prevented and partially reversed the murine ACM phenotypes. Our findings introduce what we believe to be a new pathway for ACM, a role of ankyrin-B in cardiac structure and signaling, a molecular link between ankyrin-B and \u3b2-catenin, and evidence for targeted activation of the WNT/\u3b2-catenin pathway as a potential treatment for this disease

Progesterone after previous preterm birth for prevention of neonatal respiratory distress syndrome (PROGRESS): a randomised controlled trial

Background: Neonatal respiratory distress syndrome, as a consequence of preterm birth, is a major cause of early mortality and morbidity during infancy and childhood. Survivors of preterm birth continue to remain at considerable risk of both chronic lung disease and long-term neurological handicap. Progesterone is involved in the maintenance of uterine quiescence through modulation of the calcium-calmodulin-myosin-light-chain-kinase system in smooth muscle cells. The withdrawal of progesterone, either actual or functional is thought to be an antecedent to the onset of labour. While there have been recent reports of progesterone supplementation for women at risk of preterm birth which show promise in this intervention, there is currently insufficient data on clinically important outcomes for both women and infants to enable informed clinical decision-making. The aims of this randomised, double blind, placebo controlled trial are to assess whether the use of vaginal progesterone pessaries in women with a history of previous spontaneous preterm birth will reduce the risk and severity of respiratory distress syndrome, so improving their infant's health, without increasing maternal risks. Methods Design: Multicentred randomised, double blind, placebo-controlled trial. Inclusion Criteria: pregnant women with a live fetus, and a history of prior preterm birth at less than 37 weeks gestation and greater than 20 weeks gestation in the immediately preceding pregnancy, where onset of labour occurred spontaneously, or in association with cervical incompetence, or following preterm prelabour ruptured membranes. Trial Entry & Randomisation: After obtaining written informed consent, eligible women will be randomised between 18 and 23+6 weeks gestation using a central telephone randomisation service. The randomisation schedule prepared by non clinical research staff will use balanced variable blocks, with stratification according to plurality of the pregnancy and centre where planned to give birth. Eligible women will be randomised to either vaginal progesterone or vaginal placebo. Study Medication & Treatment Schedules: Treatment packs will appear identical. Woman, caregivers and research staff will be blinded to treatment allocation. Primary Study Outcome: Neonatal Respiratory Distress Syndrome (defined by incidence and severity). Sample Size: of 984 women to show a 40% reduction in respiratory distress syndrome from 15% to 9% (p = 0.05, 80% power). Discussion: This is a protocol for a randomised trial.Jodie M. Dodd, Caroline A. Crowther, Andrew J. McPhee, Vicki Flenady, and Jeffrey S. Robinso

Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09‐related pneumonia: an individual participant data meta‐analysis

BACKGROUND: The impact of neuraminidase inhibitors (NAIs) on influenza‐related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection. METHODS: A worldwide meta‐analysis of individual participant data from 20 634 hospitalised patients with laboratory‐confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) ‘pandemic influenza’. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. RESULTS: Of 20 634 included participants, 5978 (29·0%) had IRP; conversely, 3349 (16·2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0·83 (95% CI 0·64–1·06; P = 0·136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0·72 (0·44–1·17; P = 0·180)] or likelihood of requiring ventilatory support [adj. OR = 1·17 (0·71–1·92; P = 0·537)], but early treatment versus later significantly reduced mortality [adj. OR = 0·70 (0·55–0·88; P = 0·003)] and likelihood of requiring ventilatory support [adj. OR = 0·68 (0·54–0·85; P = 0·001)]. CONCLUSIONS: Early NAI treatment of patients hospitalised with A(H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support